This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
After 92% YTD Surge, Is Tempus AI a Buy on Trump's Executive Order?
by Urmimala Biswas
President Donald Trump's new executive order aiming to cut U.S. drug prices could benefit Tempus AI.
These AI Stocks Posted Robust Results: Time to Buy?
by Derek Lewis
Several AI-related stocks have posted robust results throughout the Q1 earnings cycle, a list that includes Palantir and Tempus AI. Given their results, it's impossible to deny the staying power of AI, which is still likely in its early innings.
Tempus AI Stock Surges 43% in Q1: Buy Now or Wait for Earnings?
by Urmimala Biswas
TEM's Genomics unit is expected to report strong growth for the first quarter, banking on continued unit growth pick-up.
The Zacks Analyst Blog Highlights Tempus AI, AstraZeneca, iRhythm Technologies and SOPHiA GENETICS
by Zacks Equity Research
Tempus AI, AstraZeneca, iRhythm Technologies and SOPHiA GENETICS are included in this Analyst Blog.
Tempus AI Stock Sees 21% Gain in 3 Days: Is it a Buy After AZN Deal?
by Urmimala Biswas
TEM stock rises for three successive days. Should you expect more upside ahead, or is it time to dump Tempus AI?
Tempus AI vs. Doximity: Which AI in Healthcare Stock is a Better Buy?
by Urmimala Biswas
Both TEM and DOCS are technology-intensive healthcare companies leveraging artificial intelligence to enhance their platforms. Which one is a better investment? Let's see.
Beyond Tempus AI: 2 Health IT Stocks Poised for Growth in 2025
by Urmimala Biswas
AI-driven healthcare companies like Butterfly Network and Health Catalyst have all the qualities to emerge as the next big players.
Tempus AI Surges 43% YTD: Is it the Right Time to Invest in the Stock?
by Urmimala Biswas
The February 2025 acquisition of Ambry Genetics further expands TEM's genomics capabilities with a West Coast lab and enhanced inherited risk testing.
Tap Billion-Dollar AI Opportunity in Oncology: Stocks in the Spotlight
by Urmimala Biswas
Betting on AI-driven precision oncology companies presents a compelling long-term opportunity for investors. Some of the stocks in focus are BTAI, TEM and DGX.
Tempus AI Surges 40% YTD: Are New Strategic Deals a Buy Signal?
by Urmimala Biswas
The market's appetite for AI applications in healthcare is rapidly increasing, with TEM emerging as a top contender in this high-growth sector.
Tempus Stock May Rise on the Acquisition of AI-Driven Deep 6 AI
by Zacks Equity Research
TEM announces the acquisition of Deep 6 AI, enhancing its AI-driven clinical trial matching capabilities to accelerate patient recruitment and revolutionize precision medicine.
Tempus AI Falls 15% on Weak Q4 but EBITDA View Strong: Buy the Dip?
by Urmimala Biswas
The acquisition of Ambry Genetics strengthens Tempus AI's genomics capabilities by adding a West Coast lab and expanding inherited risk testing.
Tempus Stock Falls as Q4 Earnings & Revenues Miss Estimates
by Zacks Equity Research
TEM's fourth-quarter results reflect strong segmental performance. However, the company continues to incur losses at the operational level.
Tempus AI Mixes Healthcare with AI
by David Bartosiak
Does this AI company have what it takes to breakout?
Will Cheaper AI Models Like DeepSeek Become a Boon? 3 Stocks to Watch
by Indrajit Bandyopadhyay
As costs related to AI models may come down, as is evident from the cheaper DeepSeek model from China, MedTech companies developing AI-based solutions like SYK, BSX and TEM are likely to gain.
Tempus AI Stock Before Q4 Earnings: To Buy or Not to Buy?
by Urmimala Biswas
TEM's Genomics unit is expected to report strong growth for the fourth quarter, banking on continued unit growth pick-up.
TEM Stock Rises on Launch of AI-Powered Health Concierge App
by Zacks Equity Research
Tempus AI announces the launch of olivia, an AI-enabled personal health concierge app designed to revolutionize patient care and engagement nationwide.
TEM Stock Declines Following Preliminary Q4 Sales Miss
by Zacks Equity Research
Tempus reports strong 2024 growth and unveils a bold 2025 outlook with 75% revenue growth and innovative diagnostics.
Tempus AI Stock Falls Despite Collaboration Announcement With Genialis
by Zacks Equity Research
TEM announces a collaboration with Genialis to develop new RNA-based algorithms across cancer types.
The Zacks Analyst Blog Highlights Tempus AI, iRhythm Technologies and SOPHiA GENETICS
by Zacks Equity Research
Tempus AI, iRhythm Technologies and SOPHiA GENETICS are part of the Zacks top Analyst Blog.
Tempus AI Stock Surges 23% in 6 Months: Should You Snap It Up Now?
by Urmimala Biswas
TEM's cutting-edge product lines and strategic plans are positioning it for long-term success.
5 Top AI-in-MedTech Stocks for Big Gains in 2025: MDT, BSX & More
by Indrajit Bandyopadhyay
Here we discuss five medical stocks - MDT, BSX, BDX, GEHC and TEM - incorporating AI in their workflows. These are likely to gain in 2025 as AI helps cut costs and improve patient care.
Tempus AI Stock Plunges 28.9% in Three Months: What's Next?
by Debanjana Dey
TEM is enhancing its offerings and expanding the breadth of products and services to improve patient care. However, macro challenges are likely to hurt its performance.
Will Ambry Genetics Acquisition Drive Tempus AI's Prospects?
by Zacks Equity Research
TEM acquires Ambry Genetics, expanding its testing portfolio and redefining precision medicine.
Tempus Stock Declines Despite Q3 Earnings & Revenues Beat Estimates
by Zacks Equity Research
TEM's third-quarter results reflect strong segmental performance. However, the company continues to incur losses at the operational level.